Exocrine pancreatic insufficiency, which occurs in approximately 20% of the patients with GEP-NENs receiving SSAs octreotide and lanreotide, is an underestimated condition. The clinical picture of EPI in these patients may overlap with tumor-related symptoms and common direct SSAs’ side effects, such as diarrhea, abdominal pain, bloating, and flatulence. Early recognition of EPI is mandatory since it may negatively affect patients’ quality of life, nutritional status, and long-term clinical outcomes.

Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia / Panzuto, F.; Magi, L.; Rinzivillo, M.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 20:4(2021), pp. 383-386. [10.1080/14740338.2021.1881478]

Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia

Panzuto F.
;
Magi L.;Rinzivillo M.
2021

Abstract

Exocrine pancreatic insufficiency, which occurs in approximately 20% of the patients with GEP-NENs receiving SSAs octreotide and lanreotide, is an underestimated condition. The clinical picture of EPI in these patients may overlap with tumor-related symptoms and common direct SSAs’ side effects, such as diarrhea, abdominal pain, bloating, and flatulence. Early recognition of EPI is mandatory since it may negatively affect patients’ quality of life, nutritional status, and long-term clinical outcomes.
antineoplastic agents; exocrine pancreatic insufficiency; humans; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; somatostatin; stomach neoplasms
01 Pubblicazione su rivista::01m Editorial/Introduzione in rivista
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia / Panzuto, F.; Magi, L.; Rinzivillo, M.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 20:4(2021), pp. 383-386. [10.1080/14740338.2021.1881478]
File allegati a questo prodotto
File Dimensione Formato  
Panzuto_Exocrine-pancreatic-insufficiency_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 739.43 kB
Formato Adobe PDF
739.43 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1611811
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact